Danaher Corporation - DHR STOCK NEWS

Danaher (NYSE: DHR) has reported its Q1 2025 financial results, with net earnings of $1.0 billion ($1.32 per diluted share) and non-GAAP adjusted diluted earnings of $1.88 per share. Revenues saw a slight decrease of 1.0% to $5.7 billion, while non-GAAP core revenue remained flat year-over-year. The company generated strong cash flows with operating cash flow of $1.3 billion and non-GAAP free cash flow of $1.1 billion.

Looking ahead, Danaher expects low-single-digit core revenue growth for Q2 2025 and maintains its full-year 2025 core revenue growth projection of approximately 3%. The company has initiated full-year adjusted diluted earnings guidance of $7.60 to $7.75 per share.

Danaher (NYSE: DHR) has announced its upcoming first quarter 2025 earnings conference call, scheduled for Tuesday, April 22, 2025, at 8:00 a.m. ET. The hour-long presentation will include discussions on financial performance and future expectations.

The event will be accessible through a webcast on Danaher's website under the 'Investors' section, accompanied by slide presentations. Participants can join via phone by dialing 800-245-3047 (U.S.) or +1 203-518-9765 (international) using Conference ID: DHRQ125.

A replay will be available until May 6, 2025. The earnings press release, webcast slides, and related materials will be posted on Danaher's website at 6:00 a.m. ET on the day of the call.

Beckman Coulter Diagnostics has received FDA 510(k) clearance for its new DxC 500i Clinical Analyzer, an integrated clinical chemistry and immunoassay system. The analyzer features:

• Throughput capacity of 800 clinical chemistry tests and 100 immunoassay tests per hour
• FlexMode operations for test prioritization
• Dynamic sample handler for automated repeats and re-runs
• Intuitive interface with proactive task indicators

The system is designed to support networked laboratory operational models, particularly relevant as approximately 45% of U.S. clinical laboratories (over 11,000) are part of Integrated Delivery Networks (IDNs). The analyzer has been available in CE mark countries since July 2024 and builds upon the previously released DxC 500 AU Chemistry Analyzer technology.

Danaher (NYSE: DHR) has announced that its President and CEO, Rainer M. Blair, will deliver a presentation at the upcoming TD Cowen Healthcare Conference in Boston, Massachusetts. The presentation is scheduled for Wednesday, March 5, 2025, at 10:30 a.m. ET.

The event will feature a simultaneous webcast accessible to interested parties through the 'Investors' section of Danaher's website under 'Events & Presentations' at www.danaher.com.

Danaher (NYSE: DHR) has appointed Charles Lamanna to its Board of Directors and the Board's Science & Technology Committee. Lamanna currently serves as Corporate Vice President, Business & Industry Copilot at Microsoft, where he leads product innovation in AI-powered business applications, low-code platforms, and autonomous agents.

Lamanna oversees design, product development, and engineering of Microsoft's key technologies, including Power Platform, Dynamics 365, and Copilot Studio. He previously founded MetricsHub, a public cloud management solution acquired by Microsoft in 2013. The Notre Dame computer science graduate brings significant AI and technology expertise to Danaher's board as the company aims to leverage artificial intelligence to improve human health and deliver long-term stakeholder value.

Danaher (NYSE: DHR) has announced an increase in its regular quarterly cash dividend. The Board of Directors approved a dividend of $0.32 per share of common stock, representing an 18.5% increase from the previous payment of $0.27. The dividend will be payable on April 25, 2025 to shareholders of record as of March 28, 2025.

TriLink BioTechnologies, a Maravai LifeSciences (NASDAQ: MRVI) company, has entered into a non-exclusive License and Supply Agreement with Aldevron for CleanCap® mRNA capping technology. The agreement allows Aldevron to use TriLink's patented CleanCap® analogs in mRNA development and manufacturing services through Phase III programs.

The agreement covers CleanCap® M6, CleanCap® AG 3'OMe, CleanCap® AG, and CleanCap® AU cap analogs. The CleanCap® technology delivers optimal 5'Cap structures with over 95% efficiency, improving mRNA yield and process time compared to traditional methods. The technology has been used in over 350 preclinical and clinical programs and is featured in most approved COVID-19 mRNA and saRNA vaccines.

Notably, the recently introduced CleanCap® M6 (May 2023) has demonstrated increased mRNA expression by more than 30% compared to enzymatic capping methods.

Danaher (NYSE: DHR) reported its Q4 and full-year 2024 results, showing mixed performance. In Q4 2024, revenues increased 2.0% year-over-year to $6.5 billion, with non-GAAP core revenue up 1.0%. Q4 net earnings reached $1.1 billion, or $1.49 per diluted share, with non-GAAP adjusted EPS of $2.14.

For full-year 2024, the company reported flat revenues at $23.9 billion, while non-GAAP core revenue decreased 1.5%. Net earnings were $3.9 billion, or $5.29 per diluted share, with non-GAAP adjusted EPS of $7.48. Operating cash flow was strong at $6.7 billion, with free cash flow of $5.3 billion.

Looking ahead to 2025, Danaher expects Q1 core revenue to decline low-single digits year-over-year, but projects full-year core revenue growth of approximately 3%.

Aldevron has launched Alchemy™, a revolutionary cell-free DNA technology for research grade applications. This innovative technology cuts linear DNA manufacturing time by over 50 percent while producing cleaner, safer DNA templates for mRNA synthesis.

The technology utilizes rolling circle amplification for DNA template production, eliminating the need for cells in DNA amplification. Key benefits include faster turnaround times, lower endotoxin levels, reduced host cell-derived impurities, and high-quality control specifications. The research grade version is currently available to support development and preclinical programs, with a cGMP offering planned for 2025 to support clinical applications.